MedPath

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Not Applicable
Suspended
Conditions
Type 2 Diabetes
Interventions
Device: Duodenal Mucosal Resurfacing (DMR)
Device: Duodenal Mucosal Resurfacing (Sham)
Registration Number
NCT04419779
Lead Sponsor
Fractyl Health Inc.
Brief Summary

The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more glucose lowering agents. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 48 weeks post treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
320
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Duodenal Mucosal Resurfacing (DMR)Duodenal Mucosal Resurfacing (DMR)Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with inadequately controlled type 2 diabetes.
Duodenal Mucosal Resurfacing Sham (Sham)Duodenal Mucosal Resurfacing (Sham)Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with inadequately controlled type 2 diabetes.
Primary Outcome Measures
NameTimeMethod
Demonstrate superiority of Revita DMR to sham in improving glycemic controlBaseline to Week 24

Change from baseline in HbA1c at Week 24

Secondary Outcome Measures
NameTimeMethod
Demonstrate superiority of Revita DMR to sham in weight loss at 24 weeksBaseline to Week 24

Percentage of total body weight loss (%TBWL) from baseline at Week 24

Demonstrate superiority of Revita DMR to sham in achieving target HbA1c at 24 weeksBaseline to Week 24

The proportion of subjects who achieve an HbA1c of ≤7.0% at Week 24

To demonstrate superiority of Revita DMR to sham in elimination of insulin use at 24 weeks in those subjects on insulin at baselineBaseline to Week 24

4. The proportion of subjects who discontinued insulin at Week 24 in those subjects on insulin at baseline

Demonstrate superiority of Revita DMR to sham in fasting glucose at 24 weeksBaseline to Week 24

Change from baseline in fasting plasma glucose (FPG) at Week 24

Trial Locations

Locations (58)

Helios CR, Inc

🇺🇸

Phoenix, Arizona, United States

HonorHealth Research Institute

🇺🇸

Scottsdale, Arizona, United States

Mayo Clinic Arizona

🇺🇸

Scottsdale, Arizona, United States

Angel City Research , Inc.

🇺🇸

Los Angeles, California, United States

UCLA Health

🇺🇸

Los Angeles, California, United States

Care Access Santa Clarita

🇺🇸

Newhall, California, United States

Hoag Hospital

🇺🇸

Newport Beach, California, United States

Stanford University Medical Center

🇺🇸

Redwood City, California, United States

Mills Peninsula Health Center

🇺🇸

San Mateo, California, United States

Northeast Research Institute, Llc

🇺🇸

Fleming Island, Florida, United States

Jacksonville Center for Clinical Research

🇺🇸

Jacksonville, Florida, United States

University of Miami

🇺🇸

Miami, Florida, United States

West Orange Endocrinology

🇺🇸

Ocoee, Florida, United States

Advent Health Orlando

🇺🇸

Orlando, Florida, United States

Synexus Research

🇺🇸

Orlando, Florida, United States

Northwestern Unviersity

🇺🇸

Evanston, Illinois, United States

AHN - Avon

🇺🇸

Avon, Indiana, United States

Investigators Research Group

🇺🇸

Brownsburg, Indiana, United States

AHN- Franklin

🇺🇸

Franklin, Indiana, United States

AHN - Greenfield

🇺🇸

Greenfield, Indiana, United States

Indiana University School of Medicine

🇺🇸

Indianapolis, Indiana, United States

AHN - Muncie

🇺🇸

Muncie, Indiana, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

Tulane University

🇺🇸

New Orleans, Louisiana, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Alcanza Clinical Research, LLC

🇺🇸

Methuen, Massachusetts, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Jefferson City Medical Group

🇺🇸

Jefferson City, Missouri, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

IMA Clinical Research St. Louis

🇺🇸

Saint Louis, Missouri, United States

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Endocrine Associates of West Village

🇺🇸

Long Island City, New York, United States

NYU Langone Gastroenterology Associates

🇺🇸

New York, New York, United States

Synexus Clinical Research, New York

🇺🇸

New York, New York, United States

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

Weill Cornell Medicine

🇺🇸

New York, New York, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

M3 Wake Research

🇺🇸

Raleigh, North Carolina, United States

AcellaCare Salisbury

🇺🇸

Salisbury, North Carolina, United States

AcellaCare Piedmont

🇺🇸

Statesville, North Carolina, United States

AcellaCare Wilmington

🇺🇸

Wilmington, North Carolina, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Preferred PCP - Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

Preferred Primary Care Physicians

🇺🇸

Pittsburgh, Pennsylvania, United States

Care Access Warwick

🇺🇸

Warwick, Rhode Island, United States

Baylor St. Luke's Medical Center

🇺🇸

Houston, Texas, United States

Biopharma Informatic, Llc

🇺🇸

Houston, Texas, United States

Simcare Medical Research, Llc.

🇺🇸

Sugar Land, Texas, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

West Virginia University

🇺🇸

Morgantown, West Virginia, United States

Cliniques Universitaires de Bruxelles Hopital Erasme

🇧🇪

Bruxelles, Belgium

University College Dublin

🇮🇪

Dublin, Ireland

Italy Gemelli

🇮🇹

Roma, Italy

Universiteit Van Amsterdam Academisch Medisch Centrum

🇳🇱

Amsterdam, Netherlands

University Hospital Zurich

🇨🇭

Zürich, Switzerland

Cleveland Clinic London

🇬🇧

London, England, United Kingdom

King's College Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath